Trial Profile
A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Semapimod (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CD02
- Sponsors Ferring Pharmaceuticals
- 10 May 2014 New trial record